

1 **Report of unexpected findings after cardiac stem cell injections in a preclinical model**

2 Mira van der Naald<sup>1</sup>, Hans T van den Broek<sup>1</sup>, John LM Bemelmans<sup>2</sup>, Klaus Neef<sup>1</sup>, Maarten H Bakker<sup>3</sup>,  
3 Patricia YW Dankers<sup>3</sup>, Adriaan O Kraaijeveld<sup>1</sup>, Steven AJ Chamuleau<sup>4</sup>

4 <sup>1</sup>Department of Cardiology, University Medical Center Utrecht, the Netherlands

5 <sup>2</sup>Department of Nuclear Medicine, University Medical Center Utrecht, the Netherlands

6 <sup>3</sup> Institute for Complex Molecular Systems, Department of Biomedical Engineering, Eindhoven University of Technology,  
7 Eindhoven, the Netherlands

8 <sup>4</sup> Department of Cardiology, Amsterdam University Medical Center, the Netherlands

9

10

11 Key words: Cardiac repair, regenerative therapy, retention, intramyocardial injection.

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47 **Corresponding author**

48 Steven AJ Chamuleau

49 [s.a.j.chamuleau@amsterdamumc.nl](mailto:s.a.j.chamuleau@amsterdamumc.nl)

50

51 **ABBREVIATIONS**

52	UPy-gel	ureido-pyrimidinone hydrogel
53	LAD	left anterior descending artery
54	MSC	mesenchymal stromal cells
55	PBS	phosphate-buffered saline
56	CSFE	carboxyfluorescein succinimidyl ester
57	MI	myocardial infarction
58	PET-CT	positron emission tomography/computed tomography
59	CT	computed tomography
60	FDG	fluorodeoxyglucose

61 **ABSTRACT**

62 **Introduction** Cardiac regenerative therapy is a proposed therapy for ischemic heart disease. So far efficacy  
63 has been low and this might partly be explained by low cardiac cell retention. In this study we aimed to  
64 investigate if cardiac cell retention improves using ureido-pyrimidinone units (UPy-gel) as a cell carrier.

65 **Methods** We used an ischemia-reperfusion model. Pigs were randomized to intramyocardial injections  
66 with mesenchymal stromal cells (MSC) labelled with both Indium-111 and a fluorescent tracer in either  
67 PBS or in the UPy-gel. After 4 hours, a total body scintigraphy was performed to determine the cardiac  
68 cell retention and histology was obtained.

69 **Results** In the first 4 pigs, we noticed focused areas of radio activity (hotspots) outside the heart in both  
70 the control and UPy-gel arm, and decided to interrupt the study. At histology we confirmed one hotspots  
71 to be located in a lymph node. No satisfactory explanation for these, potentially harmful, hotspots was  
72 found.

73 **Conclusion** This study was interrupted due to unexpected extra-cardiac hotspots. Although we do not  
74 have a conclusive explanation for these findings, we find that sharing these results is important for future  
75 research. We recommend to use total body imaging in future retention studies to confirm or reject the  
76 occurrence of extra-cardiac cell accumulation after intramyocardial cell injection and discover the  
77 pathophysiology and its clinical implications.

## 78 INTRODUCTION

79 Cardiac cell therapy has been a promising therapy to repair the damaged heart. However, efficacy has  
80 been low in preclinical and clinical trials<sup>1,2</sup>. One possible explanation for the observed low efficacy could  
81 be inefficient cell delivery. We previously showed that cardiac retention after intracoronary infusion or  
82 intramyocardial injection of bone marrow derived mesenchymal stromal cells (MSC) is limited to 10-  
83 15%<sup>3,4</sup>. Additionally, we showed that retrograde coronary venous infusion does not improve cardiac  
84 retention<sup>4</sup>. In this study we aim to test if delivery with a cell carrier improves cardiac retention. Here we  
85 use a pH-switchable hydrogel based on ureido-pyrimidinone units telechelically coupled to poly(ethylene  
86 glycol) (UPy-gel)<sup>5</sup>. This hydrogelator is in the liquid state at basic conditions and turns into a gel state at a  
87 lower, i.e. neutral or acidic, pH. We aimed to show increased cardiac retention when injecting MSCs  
88 combined with UPy-gel, compared to MSCs in phosphate-buffered saline (PBS) in a confirmatory pig study.  
89 We found extra-cardiac focused areas of high intensity signal (hotspots) implying extra-cardiac  
90 accumulation of cells in the first pig and confirmed this in the following 3 pigs. The hotspots were observed  
91 in both study arms. This finding was unexpected and has potential harmful clinical consequences.  
92 Therefore we decided to interrupt and de-blind this study. Here we share our unexpected findings, discuss  
93 possible explanations and provide recommendations for future research.

94

## 95 METHODS

### 96 Ethical statement

97 All experiments were performed in compliance with the “*Guide for the Care and Use of Laboratory*  
98 *Animals*”, published by the National Institutes of Health (National Institutes of Health publication 85-23,  
99 revised 1985). The protocol was approved by the Animal Experiments Committee of the Utrecht University  
100 (AVD115002015257) and registered at [www.preclinicaltrials.eu](http://www.preclinicaltrials.eu) (PCTE0000105). Protocols of comparable  
101 experiments are available online<sup>3,4,6,7</sup>.

102

### 103 Animals and housing


104 Female Yorkshire pigs (van Beek, SPF varkensfokkerij B.V. Lelystad) of approximately 70 kg were used in  
105 these experiments. Animals were housed in stables embedded with straw and enriched with rods. Animal  
106 welfare was assessed on a daily base by animal caretakers.

107

### 108 Study design

109 Myocardial infarction was induced at baseline. After 4 weeks, all surviving pigs were randomized to  
110 intramyocardial injections of mesenchymal stromal cells (MSC), radioactively labeled with Indium<sup>111</sup> and  
111 fluorescently-labeled with carboxyfluorescein succinimidyl ester (CFSE), in either a solution of 1) PBS or in  
112 2) UPy-gel (figure 1). If animals reached an human endpoint (severe immobility, severe dyspnea or  
113 cyanosis, wound infection) they were euthanized and excluded. There were no additional inclusion  
114 criteria. According to sample size calculations, 14 pigs were needed to show a 6% increase in cardiac cell  
115 retention. The alpha was set on 0.05, beta on 0.20, the standard deviation on 3 and we expected 20% of  
116 the animal to drop-out due to fatal rhythm disorders during or shortly after infarct induction. We used  
117 block randomization, generated by a computer-generated random number sequence. Animals were  
118 randomized in a one-to-one ratio. All procedures were performed by the same researchers (cell culture  
119 (KN), catheter handling (MN), cell labeling and syringe control (TB)). The researcher handling the catheter  
120 was blinded for treatment allocation. Scintigraphy analyses, including drawing the regions of interest in

121 the scintigraphy images, were performed by the same two technicians and supervised by the same nuclear  
122 medicine physician (JB), all of them were blinded for treatment allocation.  
123



124  
125 Figure 1: Study design. Ischemia/reperfusion was induced by a 90 minute occlusion of the Left Anterior Descending artery with a  
126 balloon via a percutaneous procedure. Four weeks after ischemia-reperfusion, intramyocardial injections were performed. Four  
127 hours after injections in vivo total body scintigraphy was performed, and the pigs were sacrificed for ex vivo scintigraphy of the  
128 organs and histology.

129

### 130 Anesthesia and analgesia

131 All animals were treated with amiodarone (1200 mg/day, 7 days), clopidogrel (75 mg, 3 days) and  
132 carbasalate calcium (320 mg, 1 day) prior to the myocardial infarction. Animals were anesthetized in the  
133 supine position with intramuscular ketamine (10-15 mg/kg), midazolam (0.7 mg/kg) and atropine (0.5 mg)  
134 and intravenous thiopental sodium (4 mg/kg), midazolam (10 mg) and sufentanil (0.25 mg). A bolus of  
135 amiodarone (300 mg in 30 minutes) was administered intravenously. During the procedure the animals  
136 received midazolam (1mg/kg/h), sufentanil 10 µg/kg/h) and pancuronium bromide (0.1 mg/kg/h). Heparin  
137 (5000 IU) was given every 2 hours. All animals received a butrans patch (5 µg/h). Animals were ventilated  
138 with a mixture of dioxygen (O<sub>2</sub>) and air (1:2) with a tidal volume of 10 ml/kg with 12 breaths per minute.  
139 Carbasalate calcium was continued (80 mg/day) until euthanasia.

140

### 141 Ischemia-reperfusion model

142 Animals were monitored during the entire procedure via continuous electrocardiogram, arterial pressure  
143 and capnogram. First the left coronary system was visualized via a coronary angiography. The myocardial  
144 infarction (MI) was induced by a 90-minute occlusion of the left anterior descending artery (LAD) using an  
145 angioplasty balloon. The balloon position was based on the coronary anatomy, the preferred position was  
146 after the second diagonal branch. In case of ventricular fibrillation or ventricular tachycardia without  
147 output, an electrical shock of 200 joules was delivered using an external defibrillator. Additionally, chest  
148 compressions were given and animals received amiodarone (150 mg, max 3 times), adrenaline (0.1 mg)  
149 and/or atropine (0.5 mg).

150

### 151 Cell culture and labeling

152 For this experiment we used allogeneic mesenchymal stromal cells (MSCs). These were isolated from the  
153 sternum and cultured as described earlier<sup>8</sup>. Cells (1 x 10<sup>7</sup>) from passage 5-7 were used for transplantation

154 after staining with carboxyfluorescein succinimidyl ester (CFSE) (Invitrogen, Carlsbad, California, USA) on  
155 the day of the transplantation. Cells were labelled with 30 MBq In<sup>111</sup> by incubation at 37°C for 20 minutes  
156 and washed with Hank's balanced salt solution (Life Technologies Corp, Grand Island, New York, USA) to  
157 remove excess unbound In<sup>111</sup> as described before<sup>3</sup>.

158

### 159 **Hydrogel specifications**

160 The UPy-hydrogelator (SyMO-Chem BV, Eindhoven, the Netherlands) was prepared as described  
161 before<sup>5,9,10</sup>. In short, the UPy-hydrogelator was dissolved at 5 weight percentage (wt%) in phosphate  
162 buffered saline (PBS) pH 11.7 and temperature of 70 °C using a magnetic stirrer. After dissolving, the  
163 solution reaches a pH of 9.5. The solution was then cooled down. The cells were then pipetted into the  
164 solution and stirred for 10 minutes to reach uniform distribution.

165

### 166 **Intramyocardial cell injection**

167 An electromechanical map of the left ventricle was obtained using the NOGA system (Biosense Webster,  
168 Cordis, Johnson & Johnson, USA). Cells were injected in the myocardial border zone as previously defined,  
169 using the MYOSTAR® injection catheter (Biosense Webster, Cordis, Johnson & Johnson, USA)<sup>11</sup>. Per  
170 injection approximately 0.3 mL was injected, 10-12 injections were performed per pig. Needle depth was  
171 set at 5-7 mm. The cells were injected slowly, approximately 30 seconds per injection, and the injection  
172 needle was left in situ for an additional 10 seconds to avoid leakage.

173

### 174 **Nuclear imaging and analysis**

175 A scintigraphy scan, using a dual head gamma camera (Philips NM SkyLight) was performed after 4 hours  
176 to determine cell retention in the heart and other organs of interest (liver, spleen, kidneys, lung, and  
177 bladder) (figure 1). First, an in vivo total body scan was performed at 174 keV and 247 keV energy  
178 windows. After euthanizing the animal, the organs of interest were excised and scanned. Anterior and  
179 posterior images were captured for the total body scan and the ex-vivo scan of the organs. The number  
180 of counts was based on the geometrical mean of the anterior and posterior counts. Cell retention was  
181 measured by the number of counts in the region of interest as a percentage of total body activity. Analysis  
182 were performed directly after each experiments by a team blinded to treatment allocation.

183

## 184 **RESULTS**

185 We performed experiments with 4 out of 14 pigs according to protocol, with an experienced team and  
186 did not encounter any obvious technical issues. After analyses of our first results we found focused areas  
187 of radio-activity (hotspots) outside the heart (figure 2). These hotspots were distributed throughout the  
188 body, including the abdomen, head and extremities. We did not expect to find any hotspots outside the  
189 target organs, and suggested this can compromise the value of this study. We decided to interrupt and  
190 de-blind the study after 4 pigs to investigate a reasonable explanation for the origin of these hotspots.  
191 Since we could not find a satisfying explanation and could not rule out potential harm of these hotspots,  
192 we decided to stop the study. Ethical considerations regarding use of animal and resources also  
193 contributed to this decision.

194

### 195 **Hotspots**

196 Two authors (TB and MN) discussed the scintigraphy images and rated areas of increased signal intensity  
197 as hotspots by visual inspection. Quantification of signal intensity over background in the hotspots did not

198 occur. In the UPy-gel group we identified a total of 11 hotspots (8 and 3), compared to 3 hotspots in the  
199 PBS group (2 and 1). We tried identifying the exact location of the hotspots by obduction and with use of  
200 the scintigraphy scan. We traced one of the hotspots to a lymph node. However not all hotspots were  
201 traceable with this strategy. Histology confirmed CSFE-labelled MSCs in the retrieved hotspot (figure 3).  
202 Unfortunately, we could not perform additional imaging (i.e. computed tomography scan) within this  
203 study.

204

### 205 **Cardiac retention**

206 Whole body scintigraphy revealed that cardiac retention was low in both groups. Retention in the heart  
207 was 4.3% and 5.3% in the UPy-gel group compared to 3.4% and 4.0% in the PBS group (table 1). Cells  
208 accumulated in lungs, liver, kidney and spleen.

209

	Heart	Lungs	Kidneys	Liver	Spleen
Pig 1 (UPy)	4.3%	17.2%	2.7%	8.2%	1.6%
Pig 2 (PBS)	3.4%	18.8%	3.2%	9.5%	0.7%
Pig 3 (PBS)	4.0%	23.1%	2.9%	4.2%	1.1%
Pig 4 (UPy)	5.3%	20.4%	2.8%	4.2%	1.0%

210 Table 1: Cell retention in the target organs, measured as number of counts as percentage of number counts in the total body

211

212

213 Figure 2: Total body (including urine catheter) scintigraphy scan images 4 hours after injection. Pig 1 and pig 4 were randomized  
214 to UPy-gel injections, pig 2 and pig 3 were injected with cells in PBS. The hotspots are marked with red circles.

215

216

217 Figure 3: Histology performed on one hotspot (lymph node): Green: CSFE labeled injected MSCs. Red: CD31 endothelial vascular  
218 cells. Blue: Hoechst nuclei. Gray: Ly6G immune cells.

219

### 220 **Tracing of UPy-gel**

221 We hypothesized that the UPy-gel would turn into a gel state immediately after injection and thus remain  
222 in the heart as previously shown<sup>5,10,12</sup>. We further hypothesized that the UPy-gel might have remained in  
223 the heart and only the radio-active labeled cells were distributed throughout these hotspots. We  
224 therefore performed an additional, post-hoc, in vivo experiment (n=1) to investigate whether hotspots  
225 contain UPy-gel. UPy-gel (5 wt%, pH 9.5) in combination with UPy-DOTA-Gadolinium (UPy-DOTA), which  
226 is traceable with magnetic resonance imaging (MRI), was injected in combination with radioactive labeled  
227 MSCs via intramyocardial injections, using the same number of cells and injection method as the original  
228 experiment<sup>12</sup>. Scintigraphy showed 4 intra-cardiac hotspots and 1 extra-cardiac hotspot in the  
229 mediastinum (figure 4A). An MRI of the heart confirmed the intra-cardiac hotspots contained UPy-gel. No  
230 additional imaging techniques or imaging of the extra-cardiac hotspot were performed in this experiment.

231

232

233 Figure 4A (left): Scintigraphy image of post-hoc experiment with 1 pig using UPy-DOTA. Figure 4B (right): Short axis 3D viability  
234 scan with SENSE of post-hoc experiment with 1 pig using UPy-DOTA.

235

### 236 **DISCUSSION**

237 With this study we aimed to show increased cardiac retention of cells using a cell carrier in an animal  
238 model. We found extra-cardiac hotspots in the first 4 out of 14 pigs, in both the PBS and the UPy-gel

239 group. Additionally, the cardiac retention in these four pigs was lower than expected based on previous  
240 experiments using the same protocols. We could not find a satisfactory explanation for these findings and  
241 propose these results potentially compromise the value of this study. Therefore we decided to interrupt  
242 this study. Here we share our unexpected findings, not only because we find sharing (unexpected) results  
243 contributes to transparent research, but we also propose these findings demand further research to  
244 confirm the safety of intramyocardial cell injections in this model.

245

#### 246 **Extra-cardiac hotspots**

247 Tracing of cells after cardiac transplantation has been performed in several animal studies and a little  
248 number of clinical studies. Based on these previous studies, we know that cardiac retention is low and  
249 most cells can be traced back in the lungs, intestine, kidney, bladder and liver<sup>3,13-16</sup>. We expected to find  
250 diffusely distributed radio-activity outside the heart. Surprisingly, in the present study we found focused  
251 areas of radio-activity outside the heart (hotspots). Four potential explanations were considered: arterial  
252 embolisms, role of the hydrogel, venous-lymphatic spill, or technical issues. First, the cells could have  
253 formed clots in the myocardium and leak back in the left ventricle (or pushed out of the myocardium by  
254 cardiac contraction) through the injection site, causing potential harmful arterial embolisms. We could  
255 not rule out arterial obstructions in this study as we did not perform CT-angiography. Importantly, in  
256 clinical studies over 2600 people received cardiac cell transplantation, of which over 200 patients received  
257 percutaneous intramyocardial cell injections. In these studies cell therapy seems to be safe and did not  
258 show a major risk of embolisms<sup>17</sup>. Second, we considered the hydrogel to contribute to these hotspots.  
259 We found hotspots in the study arm without the use of this hydrogel. We re-analyzed data of our previous  
260 retention study with intramyocardial injections of mesenchymal stromal cells in PBS with a comparable  
261 study protocol, but without the use of a hydrogel carrier<sup>3</sup>. Although this was not reported specifically, in  
262 hindsight hotspots were also visible. Taken together, we propose that it is unlikely that the hydrogel  
263 plays a role in the formation of hotspots. Third, we hypothesized that the cells could have entered the  
264 venous system of the heart. Involvement of the lymphatic system is suggested to explain the prominently  
265 right-sided distribution of cells<sup>18</sup>. Possibly, the lymphatic system could then play a role in formation of  
266 hotspots, as we confirmed one extracardiac hotspot to be located in a lymph node. A clinical study that  
267 traced cells and performed total body imaging after intracoronary infusions, which is expected to have  
268 comparable venous drainage, did not show any extra-cardiac hotspots and could not provide evidence of  
269 involvement of the lymphatic system<sup>15</sup>. The fourth explanation could be technical issues. We have a team  
270 of skilled technicians and researchers with abundant expertise in translational studies for cardiac  
271 regeneration. Experiments are conducted according to strict protocols<sup>6,7</sup>. With these measures we limited  
272 the risk of a procedural flaw. Hotspots were, when looking back at previous work, only found in studies  
273 with intramyocardial injections. We considered the possibility of a technical failure of these injection  
274 catheters. High pressure is used to inject the product through the catheters, that potentially could have  
275 led to failure (e.g. damaged lumen or damaged injection needle). However, we exclude such technical  
276 issue since we checked and flushed all catheters after the procedures and did not find any  
277 problem/inconsistency.

278

279 Three additional studies were found that performed percutaneous intramyocardial cell injections and  
280 performed total body imaging (table 2)<sup>13,14,19</sup>. All three studies were performed in pigs and used the same  
281 MYOSTAR® catheter to perform cell injections. Collantes et al applied positron emission  
282 tomography/computed tomography (PET-CT), allowing 3D visualisation of all tissues<sup>14</sup>. This study



283 describes high radioactivity concentrations in mediastinal lymph nodes. Perin et al used a reporter gene,  
 284 which passes on to daughter cells during proliferation, and performed repetitive imaging over time. They  
 285 described involvement of the lymphatic system around the heart and cervical region<sup>19</sup>. It should be noted  
 286 that the distribution of the hotspots seems to be different in our study, as not all hotspots in our study  
 287 are located in the mediastinum. Nevertheless, this supports one of our theories that the lymphatic system  
 288 plays a role. Interestingly, Lyngbæk et al did not report extra-cardiac hotspots<sup>13</sup>. A CT-angiography to rule  
 289 out arterial embolisms was not performed in any of these studies.  
 290  
 291

	Present study	van der Spoel <sup>3</sup>	Lyngbæk <sup>13</sup>	Collantes <sup>14</sup>	Perin <sup>19</sup>
<b>Porcine model</b>	I/R	I/R	Healthy	I/R	I/R
<b>Cells</b>	Mesenchymal stromal cells	Mesenchymal stromal cells	Mesenchymal stromal cells	Cardiac stem/progenitor cells	Mesenchymal stromal cells
<b>Cell donor</b>	Allogeneic	Allogeneic	Xenogeneic (human)	Allogeneic	Autologous
<b>Number of cells</b>	1 x 10 <sup>7</sup>	1 x 10 <sup>7</sup>	1.5 to 3.3 x 10 <sup>6</sup>	50 x 10 <sup>6</sup>	1 x 10 <sup>8</sup>
<b>Label used</b>	Indium <sup>111</sup>	Indium <sup>111</sup>	Indium <sup>111</sup>	18F-FDG/GFP	sr39HSV1-tk gene
<b>Volume injected</b>	10-12 injections, 0.3 ml per injection	10-12 injections, 0.3 ml per injection	10 injections, 0.3 ml per injection	30 injections, 0.3 ml per injection	3 injections, 0.1 ml per injection
<b>Imaging technique</b>	Scintigraphy	Scintigraphy	Scintigraphy	PET-CT	[18F]FEAU PET/CT
<b>Timing of imaging</b>	4 hours after injections	4 hours after injections	0.5 hour after injection	4 hours after injections	4 hours to 5 months after injection
<b>Hotspots outside target organs</b>	Yes	Yes	No	Yes	Yes
<b>Explanation for hotspots</b>	One in lymph node, other unconfirmed	No	Not applicable	Mediastinal lymph nodes	Periaortic lymphatic structures, coronary trunks, cervical lymph nodes.

292 Table 2: Comparison of studies on in vivo cell tracking, all studies are performed in pig models. I/R = ischemie/reperfusion, PET-  
 293 CT= positron emission tomography-computed tomography.  
 294

### 295 Relatively lower cardiac retention

296 We observed in these 4 pigs that the cardiac retention is limited (3-5%), both in our control and UPy-gel  
 297 group, and lower compared to previous work<sup>3,4,13,14</sup>. Clearly, this study was not completed and no definite  
 298 conclusions can be drawn about cardiac retention. We did not find a clear explanation for the assumed  
 299 lower cardiac retention. The risk of insufficient internal study validity (because previous results were not  
 300 reproduced in our control group) contributed to the discussion to interrupt this study.  
 301

### 302 Conclusion

303 This study was initially designed to show an increased cardiac retention with the use of a hydrogel, but  
 304 was interrupted due to unexpected findings. We found extra-cardiac hotspots and a lower cardiac  
 305 retention in our control group as expected. Although we do not have a conclusive explanation for these  
 306 findings, we find that sharing these results are important for future research and contributes to  
 307 transparency. Clinical trials did not show safety issues related to intramyocardial cell injections, but only  
 308 a limited number of studies performed total body imaging and therefore extra-cardiac hotspots could  
 309 have been missed. The limited number of studies that did perform total body imaging are all preclinical  
 310 studies and have conflicting results. Most studies showed involvement of the lymphatic system, but the  
 311 distribution of cell accumulation seems to differ from our current findings. Further research should  
 312 confirm or exclude the occurrence of extra-cardiac hotspots after intramyocardial cell injection and  
 313 provide a better understanding of its pathophysiology and clinical implications, before continuing

314 research to optimize cell retention with carriers. We encourage researchers to include total body imaging  
315 in future research in this field.

316 **Acknowledgements** The authors thanks Marlijn Jansen, Joyce Visser, Martijn van Nieuwburg, Helma Avezaat and Jeroen van Ark  
317 for their excellent technical assistance and animal care. The authors also thank Monique Jacobs and Ingrid Boots for their work  
318 on the scintigraphy scans; Evelyn Velema and Joris de Brouwer for all planning and logistic affairs.  
319

320 **Funding** This research is part of Cardiovasculair Onderzoek Nederland (grant number CVON 2011-2), an initiative of the Dutch  
321 Heart Foundation, Netherlands Federation of University Medical Centres (NFU), Royal Netherlands Academy of Arts and Science  
322 (KNAW) and NWO/ZonMW.  
323

324 No human studies were carried out by the authors for this article.  
325

326 All institutional and national guidelines for the care and use of laboratory animals were followed and approved by the appropriate  
327 institutional committees.

328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379

## References

1. Jansen of Lorkeers SJ, Gho JMIH, Koudstaal S, et al. Xenotransplantation of Human Cardiomyocyte Progenitor Cells Does Not Improve Cardiac Function in a Porcine Model of Chronic Ischemic Heart Failure. Results from a Randomized, Blinded, Placebo Controlled Trial. *PLoS One*. 2015;10(12):e0143953. doi:10.1371/journal.pone.0143953
2. Gyöngyösi M, Wojakowski W, Lemarchand P, et al. Meta-Analysis of Cell-based Cardiac stem Cell Therapy (ACCURATE) in patients with acute myocardial infarction based on individual patient data. *Circ Res*. 2015;116(8):1346-1360. doi:10.1161/CIRCRESAHA.116.304346
3. van der Spoel TIG, Vrijnsen KR, Koudstaal S, et al. Transendocardial cell injection is not superior to intracoronary infusion in a porcine model of ischaemic cardiomyopathy: a study on delivery efficiency. *J Cell Mol Med*. 2012;16(11):2768-2776. doi:10.1111/j.1582-4934.2012.01594.x
4. Gathier WA, van der Naald M, van Klarenbosch BR, et al. Lower retention after retrograde coronary venous infusion compared with intracoronary infusion of mesenchymal stromal cells in the infarcted porcine myocardium. *BMJ Open Sci*. 2019;3(1):e000006. doi:10.1136/bmjos-2018-000006
5. Bastings MM, Koudstaal S, Kieltyka RE, et al. A fast pH-switchable and self-healing supramolecular hydrogel carrier for guided, local catheter injection in the infarcted myocardium. *Adv Heal Mater*. 2014;3(1):70-78. doi:10.1002/adhm.201300076
6. Koudstaal S, Jansen of Lorkeers S, Gho JM, et al. Myocardial infarction and functional outcome assessment in pigs. *J Vis Exp*. 2014;(86). doi:10.3791/51269
7. Pape AC, Bakker MH, Tseng CC, et al. An Injectable and Drug-loaded Supramolecular Hydrogel for Local Catheter Injection into the Pig Heart. *J Vis Exp*. 2015;(100):e52450. doi:10.3791/52450
8. Feyen DAM, van den Akker F, Noort W, Chamuleau SAJ, Doevendans PA, Sluijter JPG. Isolation of Pig Bone Marrow-Derived Mesenchymal Stem Cells. In: Gneocchi M, ed. *Mesenchymal Stem Cells: Methods and Protocols*. New York, NY: Springer New York; 2016:225-232. doi:10.1007/978-1-4939-3584-0\_12
9. Koudstaal S, Bastings MM, Feyen DA, et al. Sustained delivery of insulin-like growth factor-1/hepatocyte growth factor stimulates endogenous cardiac repair in the chronic infarcted pig heart. *J Cardiovasc Transl Res*. 2014;7(2):232-241. doi:10.1007/s12265-013-9518-4
10. Schotman MJG, Peters MMC, Krijger GC, et al. In Vivo Retention Quantification of Supramolecular Hydrogels Engineered for Cardiac Delivery. *Adv Healthc Mater*. 2021;10:2001987. doi:10.1002/adhm.202001987
11. van der Spoel TIG, Jansen of Lorkeers SJ, Agostoni P, et al. Human relevance of pre-clinical studies in stem cell therapy: systematic review and meta-analysis of large animal models of ischaemic heart disease. *Cardiovasc Res*. 2011;91(4):649-658. doi:10.1093/cvr/cvr113
12. Bakker MH, Tseng CCS, Keizer HM, et al. MRI Visualization of Injectable Ureidopyrimidinone Hydrogelators by Supramolecular Contrast Agent Labeling. *Adv Healthc Mater*. 2018;7(11):1701139. doi:https://doi.org/10.1002/adhm.201701139
13. Lyngbæk S, Ripa RS, Haack-Sørensen M, et al. Serial in vivo imaging of the porcine heart after human mesenchymal stromal cells. *Int J Cardiovasc Imaging*. 2010;26:273-284. doi:10.1007/s10554-009-9532-4
14. Collantes M, Pelacho B, García-Velloso MJ, et al. Non-invasive in vivo imaging of cardiac stem/progenitor cell biodistribution and retention after intracoronary and intramyocardial delivery in a swine model of chronic ischemia reperfusion injury. *J Transl Med*. 2017;15:56. doi:10.1186/s12967-017-1157-0
15. Hofmann M, Wollert KC, Meyer GP, et al. Monitoring of bone marrow cell homing into the infarcted human myocardium. *Circulation*. 2005;111(17):2198-2202. doi:10.1161/01.CIR.0000163546.27639.AA
16. Hudson W, Collins MC, deFreitas D, Sun YS, Muller-Borer B, Kypson AP. Beating and Arrested Intramyocardial Injections Are Associated with Significant Mechanical Loss: Implications for Cardiac Cell Transplantation. *J Surg Res*. 2007;142(2):263-267. doi:10.1016/j.jss.2007.03.021
17. Afzal MR, Samanta A, Shah ZI, et al. Adult bone marrow cell therapy for ischemic heart disease: Evidence and insights from randomized controlled trials. *Circ Res*. 2015;117(6):558-575. doi:10.1161/CIRCRESAHA.114.304792
18. Hou D, Youssef EA, Brinton TJ, et al. Radiolabeled Cell Distribution After Intramyocardial, Intracoronary, and Interstitial Retrograde Coronary. *Circulation*. 2005;112(9 suppl):I150-I156. doi:10.1161/CIRCULATIONAHA.104.526749
19. Perin EC, Tian M, Marini FC, et al. Imaging long-term fate of intramyocardially implanted mesenchymal stem cells in a porcine myocardial infarction model. *PLoS One*. 2011;6(9). doi:10.1371/journal.pone.0022949



Fig 1




Fig 2





Fig 3



Fig 4



bioRxiv preprint doi: <https://doi.org/10.1101/2021.10.26.461331>; this version posted October 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

40 μm

